本报时报记者 卢梦雪 见习记者 张萌 北京报道 6月4日晚，港股上市的宜宾市商业银行（下称"宜宾银行"）发布公告，宣布董事会审议通过委任蒋琳为该行行 长，并建议其担任执行董事。 这项任命终结了宜宾银行近两个月的行长空缺期。原行长杨兴旺因"个人身体原因"于今年4月8日突然辞职，而彼 时距离宜宾银行登陆港交所还未满三个月。 新任行长蒋琳的履历丰富，从政府公职人员到五粮液集团高管，再到银行掌舵者，跨越政、企、金融三大领域。 2023年9月起，蒋琳开始担任宜宾银行非执行董事，同时继续兼任五粮液集团的相关职务。履新的背后，这家新晋 港股银行面临的挑战依旧显著：2024年营业收入增速骤降至0.5%，净息差缩窄至1.71%，制造业贷款不良率大幅 攀升……蒋琳的接任能否带领宜宾银行突破增长瓶颈，仍需时间检验。 新行长就任 曾拟任副行长但未获批准 行长之位空缺近两个月后，46岁的蒋琳经宜宾银行董事会审议通过，被委任为行长，并建议担任执行董事。 早在2023年9月，宜宾市人民政府便提名蒋琳担任宜宾银行副行长、董事职务，同时免去其在五粮液集团的副总经 理、董事职务。然而，蒋琳的副行长任职资格始终未获得监管部门的核准。同月，国家金融 ...

"（端午节）放假前，每天有百把号人来找（住范儿）呢，欠了不少钱。" 6月1日下午，《每日经济新闻》记者来到住范儿上海公司所在地，发现公司大门被木板封得严严实实，守在门口的保安指着木板上的通知对记者说："也省 得你报警了，直接打派出所电话吧。" 据官网介绍，住范儿（隶属于北京水木优品装饰有限公司）是家居建材新零售服务商，于2015年10月成立，总部设立于北京，业务覆盖全国，同时在上海、 成都设立分公司，已经获金沙江创投、启承资本、华创资本、创新工场等知名机构投资。 这家由四位清华大学工科男创立的家装企业，宣称有1000万粉丝，却在创立的第十个年头，让众多装修业主、供应商维权无门。 上汽灵石坊的住范儿标牌图片来源：每经记者包晶晶摄 "需要向住建委反映情况" 位于上海市静安区灵石路699号的上汽·灵石坊，是住范儿上海旗舰店的所在地。每经记者在现场看到，"住范儿"的广告灯箱仍然在园区入口处最醒目的位 置，只是灯箱已经不再亮灯，在傍晚时分与其他广告并列在一起，倒也比较容易辨认。 当记者向园区保安打听住范儿所在的6号楼怎么走时，保安对这样的询问似乎已经相当熟悉了："公司都关了好多天了，门都已经封上了，就是前面那栋 楼。" ...

截至2025年5月23日收盘，ST岭南(002717)报收于2.08元，上涨5.05%，换手率3.71%，成交量59.32万 手，成交额1.22亿元。 岭南生态文旅股份有限公司发布了向不特定对象发行可转换公司债券2025年度第十六次临时受托管理事 务报告。广发证券作为受托管理人，依据相关法规和协议编制了此报告。报告指出，"岭南转债"无法按 期兑付，公司现有货币资金不足以偿付本息，信用评级已下调至C级。公司2024年营业收入为86,183.66 万元，同比下滑59.55%，归属于母公司股东的净利润为-98,432.98万元；2025年一季度营业收入为 6,759.91万元，同比下滑77.85%，归属于母公司股东的净利润为-6,639.73万元。公司存在持续经营风 险，2024年审计报告被出具保留意见。为"岭南转债"提供担保的资产包括募投项目公司股权、应收款项 等，但存在变现风险和不确定性。公司面临股票退市风险，若连续20个交易日收盘价低于1元，将被终 止上市。此外，公司面临大量诉讼，截至2025年5月9日，新增尚未披露的诉讼、仲裁事项涉案金额约 17,413.36万元。广发证券将持续关注并督促公司做好信息披露， ...

证券代码：002717.SZ 证券简称：ST 岭南 债券代码：128044.SZ 转债简称：岭南转债 岭南生态文旅股份有限公司 向不特定对象发行可转换公司债券 债券受托管理人 二〇二五年五月 重要声明 本报告依据《可转换公司债券管理办法》《岭南生态文旅股份有限公司与广 发证券股份有限公司关于岭南生态文旅股份有限公司 2018 年公开发行的可转换 公司债券之受托管理协议》（以下简称"受托管理协议"）《岭南生态文旅股份 有限公司公开发行可转换公司债券募集说明书》（以下简称"募集说明书"）等 相关公开信息披露文件、第三方中介机构出具的专业意见等，由债券受托管理 人广发证券股份有限公司（以下简称"广发证券"）编制。广发证券对本报告 中所包含的从上述文件中引述内容和信息未进行独立验证，也不就该等引述内 容和信息的真实性、准确性和完整性做出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相 关事宜做出独立判断，而不应将本报告中的任何内容据以作为广发证券所作的 承诺或声明。在任何情况下，投资者依据本报告所进行的任何作为或不作为， 广发证券不承担任何责任。 风险提示 一、"岭南转债"无 ...

Core Viewpoint - Despite facing significant pressure on revenue and net profit in 2024 due to industry adjustments and changes in consumer demand, the company is determined to transform into a comprehensive biopharmaceutical enterprise through innovation, optimized strategies, and international collaboration [1] Group 1: Innovation and Product Development - The company has achieved key breakthroughs in its vaccine pipeline, including the approval of a quadrivalent influenza vaccine and the acceptance of the application for a human diploid rabies vaccine [2] - The company aims to launch 1-2 self-developed products annually over the next 2-3 years to optimize its revenue structure [2] - The metabolic disease treatment sector is emerging as a new growth area, with significant progress in GLP-1 and insulin analogs, including the submission of liraglutide for market approval [2] Group 2: Risk Management Strategies - The company has implemented various measures to mitigate operational risks since the second quarter of the previous year, including enhancing communication with partners and adjusting promotional policies [3] - The company is focusing on inventory management and has initiated a "de-inventory" campaign to improve sales and reduce operational risks [4] - As of the end of Q1 2024, the company's accounts receivable have decreased to 14.6 billion, with ongoing efforts to manage aging receivables [4] Group 3: Shareholder Returns and Future Outlook - The company has prioritized shareholder returns by implementing a mid-term dividend of 479 million and completing over 300 million in share buybacks, reflecting its commitment to shareholder interests [5] - Management's proactive attitude and robust measures are expected to instill confidence in investors, with a focus on continuous R&D innovation and market expansion [5] - The company aims to achieve steady growth in performance and is committed to becoming a world-class biopharmaceutical enterprise [5]

财务指标解读 营收增长显著，业务拓展见成效 2024年，威奥股份实现营业收入1,527,834,472.45元，较上年同期的1,179,596,328.23元上涨29.52%。公 司表示，这主要得益于轨道交通设备及其延伸产业相关订单增加，以及富氧健康舱业务的持续增长。从 业务板块来看，动车组车辆配套产品收入679,065,550.07元，同比增长44.90%；检修业务收入 226,749,613.48元，增长48.50%；富氧健康舱产品收入57,833,071.28元，增长14.06%。这些数据表明公 司在主营业务上的市场拓展取得了一定成效。 净利润大幅下滑，需关注盈利持续性 归属于上市公司股东的净利润为55,375,500.17元，较上年同期的256,436,321.06元下降78.41%。公司解 释称，主要系上年同期收购唐山汽车及其子公司，产生较大营业外收入所致。若剔除这一非经常性因 素，公司的盈利能力变化更值得关注。扣除非经常性损益后的净利润为47,106,328.62元，上年同期为 -21,803,428.73元，这表明公司核心业务的盈利能力有所提升，但仍需关注盈利的持续性。 费用增长各有因，成本控制 ...

华夏时报（www.chinatimes.net.cn）记者 于娜 北京报道 "我们医院目前正常接诊，没有变化。"北京三博脑科医院的一位内部人员告诉《华夏时报》记者。对于董事长张 阳被留置、立案调查一事给公司经营及控制权带来的影响等问题，《华夏时报》记者联系采访三博脑科，截至发 稿未收到回复。 民营医院大佬"落马" 公开资料显示，张阳于1965年10月出生，高级工商管理专业，硕士研究生学历。2003年，张阳与北京天坛医院三 位博士生导师共同创立了三博脑科。 三博脑科注册地为北京市海淀区，主要从事以神经专科为特色的临床医疗服务，主要产品包括医疗服务、药品、 供应链、其他业务。目前，三博脑科在北京、重庆、昆明、福建、成都和河南共运营了8家医院。 张阳于2004年至2025年3月，任三博脑科总经理；2014年至今，任三博脑科董事长。同时，张阳担任中国非公立医 疗机构协会副会长、中国医院协会民营医院管理分会副会长、北京市非公立医疗机构协会终身名誉会长。 据2024年年报披露，张阳直接持有公司股份10.59%，与于春江、栾国明、石祥恩为一致行动人，构成对公司的共 同控制。公司2023年4月27日公告的《招股说明书》披露了 ...

Core Viewpoint - Guilin Tourism has reported significant declines in multiple financial metrics for the year 2024, indicating severe operational challenges faced by the company [1][17]. Financial Performance - The company achieved operating revenue of 431,675,114.43 yuan, a decrease of 7.58% from 467,103,562.89 yuan in the previous year, primarily due to intensified regional market competition and a significant flood in Guilin, leading to an 8.12% drop in visitor numbers [1]. - The net profit attributable to shareholders was -204,463,086.00 yuan, a drastic decline of 1,830.70% compared to 16,376,004.51 yuan last year, driven by reduced visitor numbers, decreased investment income, and substantial impairment losses [1][2]. - The non-recurring net profit was -199,680,189.69 yuan, down 2,625.31% from 12,469,293.04 yuan, indicating a sharp decline in core business profitability [2]. - Basic earnings per share were -0.4368 yuan, a decrease of 1,833.33% from 0.0350 yuan, reflecting severe impacts on shareholder returns [3]. Cost and Expense Analysis - Sales expenses decreased by 24.41% to 17,022,638.81 yuan, which may hinder market promotion efforts in a competitive tourism market [4]. - Management expenses slightly decreased by 1.58% to 99,903,420.29 yuan, suggesting potential for improved operational efficiency [5]. - Financial expenses were reduced by 5.53% to 34,366,636.52 yuan, but the company still faces significant long-term debt of 644,150,000.00 yuan, indicating ongoing debt pressure [6]. Cash Flow Situation - The net cash flow from operating activities was 85,377,737.78 yuan, down 29.41%, indicating weakened cash generation capabilities [9]. - The net cash outflow from investing activities increased to -45,159,872.91 yuan, necessitating attention to investment project effectiveness [10]. - The net cash flow from financing activities improved to -52,761,033.85 yuan from -77,125,143.42 yuan, but remains negative, highlighting the need for better funding strategies [11]. Industry Challenges - The tourism industry is highly susceptible to uncontrollable risks such as natural disasters, as evidenced by the recent flood in Guilin, which poses ongoing threats to business operations [12]. - Intense competition in the tourism sector, with emerging group tourism enterprises, pressures Guilin Tourism to enhance product innovation and service quality to maintain market share [13]. - The company's diverse operations across various sectors complicate management, necessitating improved coordination and efficiency to mitigate operational risks [14]. - Price control limitations imposed by government regulations on ticket pricing challenge the company's ability to manage costs effectively [15]. Management and Development - The company reported zero R&D investment during the period, which may hinder its ability to innovate and adapt to changing consumer demands [8]. - Management compensation levels, particularly in relation to the company's performance, warrant scrutiny from investors [16].

Group 1 - iRobot's financial report raised significant doubts about its ability to continue as a going concern for at least the next 12 months, leading to a 36% drop in stock price, marking the largest single-day decline since its IPO in 2005 [1][2] - The company has faced declining market share and worsening performance due to increasing price competition from Chinese companies, despite having pioneered the home robotic vacuum market with the launch of Roomba in 2002 [1][2] - iRobot's sales for the period from October to December 2024 decreased by 44% year-over-year, falling to $17.203 million, with a net loss of $77.1 million compared to a loss of $63.59 million in the same period last year [3] Group 2 - Amazon's attempt to acquire iRobot for approximately $1.7 billion, including debt, was abandoned in January 2024 after failing to receive approval from EU competition regulators, which was seen as a potential lifeline for the company [2] - Following the failed acquisition, iRobot's CEO Colin Angle resigned, and the company implemented significant workforce reductions, cutting over half of its employees [2] - Despite launching eight new products, iRobot expressed uncertainty about their success due to factors such as consumer demand, competitive landscape, macroeconomic conditions, and tariff policies, and did not provide earnings guidance for 2025 [2]